Lilly CEO Lechleiter outlines opportunities for improved health and economic growth in Asia-Pacific region
10 November 2011 | By Eli Lilly and Company
New trade agreements, effective public policies, and continued collaboration...
List view / Grid view
News
Novartis appoints Timothy Wright, M.D. as Global Head, Development, Novartis Pharmaceuticals
9 November 2011 | By Novartis
Novartis announced the appointment of Timothy Wright...
Abbott receives CE Mark for new hepatitis test
Abbott announced it has received CE Marking (Conformité Européenne) in the European Union to market a new, highly sensitive diagnostic test for detection of hepatitis B surface antigen (HBsAg). The test is performed on Abbott’s ARCHITECT® system. Hepatitis B is an inflammatory liver disease caused by the hepatitis B virus…
FDA accepts Roche’s New Drug Application for vismodegib in advanced form of skin cancer
9 November 2011 | By Roche
The vismodegib application has been granted priority review...
Daiichi Sankyo Brasil and Kyorin Pharmaceutical reach agreement in Brazil
8 November 2011 | By Daiichi Sankyo
Basic agreement reached for activities in Brazil related to the development and marketing of Imidafenacin...
AstraZeneca and Targacept announce first top-line Phase III results for TC-5214 as an adjunct treatment in patients with major depressive disorder
8 November 2011 | By AstraZeneca
Top-line results announced...
12-week on-treatment results from large Phase IIb study (COMMAND-1) of Bristol-Myers Squibb’s NS5A inhibitor daclatasvir support anti-HCV activity and safety profile observed in earlier studies
8 November 2011 | By Bristol-Myers Squibb Company
Study evaluated daclatasvir as add-on to peginterferon alfa/ribavirin (alfa/RBV)...
Novartis Phase III study shows ACZ885 helped substantially reduce steroid use in 45% of patients with serious form of childhood arthritis
7 November 2011 | By Novartis
New pivotal Phase III data announced...
GSK presents phase III results for eltrombopag in hepatitis C virus related thrombocytopenia
7 November 2011 | By GSK
Full results from ENABLE 1 and initial data from ENABLE 2 presented...
Pfizer to present clinical data from its hematology portfolio
7 November 2011 | By Pfizer
Investigator research on several pfizer compounds to be presented...
FDA approves ERBITUX® (cetuximab) for first-line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil
7 November 2011 | By Bristol-Myers Squibb Company
ERBITUX now approved for five indications across two tumor types...
Abbott presents HUMIRA® (adalimumab) Phase 3 study results
7 November 2011 | By Abbott
In ABILITY-1 Study Presented at ACR, More than Twice as Many Patients Treated with HUMIRA Met Primary Endpoint Compared to Placebo...
Interim data for Merck’s VICTRELIS™ (boceprevir) in prior null responder patients with Chronic Hepatitis C genotype 1 to be presented
5 November 2011 | By Merck
PROVIDE study results...
Treatment with Enbrel® (etanercept) shows significant and sustained clinical benefits in Rheumatoid Arthritis (RA) patients with moderately active disease
5 November 2011 | By Pfizer
PRESERVE trial results...
Positive five-year data showing effect of Viread(R) on liver fibrosis and cirrhosis caused by Chronic Hepatitis B
5 November 2011 | By
New long-term data show no development of resistance...
